NHS Opportunity: Clinical Engineer

Clinical Engineer Current Vacancies

2006-12-23:

Clinical engineers, sometimes known as bioengineers, research, design, develop and maintain technology and equipment used to meet patients clinical needs both during and after medical treatment.
The work includes building and testing prototypes, running clinical trials, evaluating results and building products.
Clinical engineers are employed by the health service, medical equipment manufacturers and university research departments.
Engineers often specialise in a particular aspect of clinical engineering such as medical physics, electronics, biomechanics or materials.
They work closely with other medical professionals, technical staff and patients.
Clinical engineers normally work 9am to 5pm, Monday to Friday. Part time work is possible.
Employers include hospitals, universities, research establishments such as the Medical Research Council, and manufacturers of medical equipment.
Some clinical engineers are self-employed and work on a consultancy basis.
In the NHS clinical engineers can be promoted to consultant-level grades.
Chartered engineers may progress into senior general management and be responsible for a team of incorporated engineers and technicians. Experienced engineers can earn between 25,000 and 37,000. Engineers with chartered status can earn over 40,000.  (Permalink)

renovo RESEARCH & DEVELOPMENT

2008-04-09: At present Renovo employs approx. 170 people. E-mail: info@renovo.com - Application, Manchester, volunteers, administrative support, data collection and analysis of the progress of volunteers in clinical trials. Contact volunteers by telephone to discuss the clinical trials. Extensive data management experience in complex Oracle Clinical procedures. Renovo aims to be first to market with a marketed pharmaceutical drug in the US and Europe to prevent and reduce scarring. Renovo plans to partner several of its' products late in clinical development with companies capable of rapid commercialisation. Products to Address All Aspects of Scarring, Not Just Skin Alone, Market Indications of High Medical Need Skin Cosmetic, plastic and reconstructive surgery, grafts, burns, minor surgery, other elective surgery, trauma, keloids. Established in-house Phase I and Phase II clinical trials. Anti-scarring and wound healing accelerant therapies arising from Renovo's discovery programmes are developed up to and including Phase II human clinical trials in house. The Market, This product has recently entered Phase III clinical development. Summary of the development status of Renovo's four leading product candidates: Juvista (Human Recombinant TGF) Renovo's lead drug candidate for the reduction of scarring, Juvista, is a therapeutic application of human recombinant Transforming Growth Factor (TGF). Renovo has signed an exclusive licensing agreement with Shire to develop and commercialise Juvista for the prevention and reduction of scarring. Renovo has safety data on more than 1,500 human subjects. Histological analysis of excised scars also supported this efficacy. Zesteem, The clinical trials unit also facilitates guided discovery. Research and Development Facilities. Future Pipeline & Ongoing Research In addition to Juvista Renovo has a large pipeline of other pharmaceuticals to accelerate healing and reduce scarring at all body sites. # Nerves - Reduction of scarring following injury to cornea or re-sculpturing laser surgery. Interested persons should apply to renovo at http://www.renovo.com/ (Permalink)